A Prospective, Open-label, Multi-center, Phase 3 Study to Evaluate the Immunogenicity and Safety of an Inactivated EV71 Enterovirus Vaccine (Envacgen®) in Children Aged 6 to <10 Years Compared to Children Aged 2 to <6 Years
Latest Information Update: 07 May 2026
At a glance
- Drugs Enterovirus A vaccine (Primary)
- Indications Enterovirus A infections
- Focus Adverse reactions; Pharmacodynamics; Registrational
- Sponsors Medigen Vaccine Biologics
Most Recent Events
- 04 May 2026 Planned End Date changed from 1 Jul 2026 to 31 Oct 2026.
- 04 May 2026 Planned primary completion date changed from 1 Feb 2026 to 31 Jul 2026.
- 04 May 2026 Status changed from recruiting to active, no longer recruiting.